Page 93
A S C R S
2 0 1 3
POST-OP RELIEF
New PostSurgical Drugs
Post-op comfort is the name of the game with these 3 new pharmaceuticals. Alcon came to the show with Ilevro (nepafenac ophthalmic suspension), a 0.3% suspension that the cataract patient uses once a day for 2 weeks to ease inflammation and relieve pain after surgery. Bausch & Lomb offers 2 new drugs to relieve post-op inflammation and pain. Lotemax Gel (loteprednol etabonate ophthalmic gel), is a 0.5% steroid solution used by the patient 4 times a day for 2 weeks after surgery. Prolensa (bromfenac ophthalmic solution), is a 0.07% once-daily eyedrop that the cataract patient uses for 2 weeks post-op. A must for patient satisfaction.
— Steven Vold, MD
-------------------------------------
injectors than are OR techs who may not be doing the procedure regularly. According to a pre-clinical study, tissue injected by Endoglide averaged just 9.1% endothelial cell damage, compared with 36.2% in tissue loaded on site. Further, the loading is done under sterile conditions, which might minimize the potential for infection. With no handling to be done in the surgical facility, all the surgeon has to do is inject the tissue with the simple, single-handed device.
AmbioDisk from IOP Ophthalmics is a suture-less amniotic membrane and a simple overlay for the ocular surface. It can be used to treat non-healing epithelial defects, neurotrophic ulcerations, corneal erosions, acute burns and post-infectious keratitis. The intact epithelial, columnar cell matrix is said to help maintain an "intact dense basement membrane" and provide a "loose collagen layer bordered by retained fibroblasts." The goal is to prevent further damage to the cornea and reduce the need for corneal transplant down the road. "It's an outpatient procedure that's preventive medicine," said one of the reps, which
